Etanercept biosimilar - Samsung Bioepis/Merck & Co

Drug Profile

Etanercept biosimilar - Samsung Bioepis/Merck & Co

Alternative Names: Benepali; Brenzys; SB-4

Latest Information Update: 23 Jul 2017

Price : $50

At a glance

  • Originator Samsung Bioepis
  • Developer Biogen; Merck & Co; Samsung Bioepis
  • Class Antipsoriatics; Antirheumatics; Disease-modifying antirheumatics; Recombinant fusion proteins
  • Mechanism of Action Immunosuppressants; Tumour necrosis factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Ankylosing spondylitis; Plaque psoriasis; Psoriatic arthritis; Rheumatoid arthritis
  • Registered Psoriasis

Most Recent Events

  • 14 Jun 2017 Updated efficacy data from a phase III trial in Rheumatoid arthritis presented at the 18th Annual Congress of the European League Against Rheumatism (EULAR-2017)
  • 24 Jan 2017 Biogen and Ewopharma signs a distribution agreement to market and sell etanercept and infliximab in Romania, Bulgaria, Croatia, Estonia, Latvia and Lithuania
  • 12 Sep 2016 Registered for Rheumatoid arthritis in Canada (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top